South Africa ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

South Africa Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The South Africa Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $192 Mn in 2022 and is projected to reach $375 Mn in 2030, exhibiting a CAGR of 8.73% during the forecast period. $38.12 Mn has been allocated to the National Health Insurance (NHI) grants over the course of the 2023–24 fiscal year in order to enhance the program. This is a little more than the $38.07 Mn that was allotted for 2022–23. Over the years 2024–26, funding for the NHI is anticipated to rise, with an allocation of $39.33 Mn. Treasury will also allocate some money to South Africa's border post medical facilities and the National Health Insurance. The 2023 Budget also detailed the Treasury's strategy for tackling the backlog that has built up in core healthcare services like surgery and oncology as a result of the pandemic's disruptions to regular healthcare services.

ADHD is a prevalent genetic neurodevelopmental disorder with a childhood onset and a high adult persistence rate. According to estimates, 5.3% of children and adolescents around the globe have ADHD. In the Limpopo province of South Africa, 5.5% of all elementary school students from all ethnic groups have ADHD. In addition to being a behavior disorder marked by impulsivity, hyperactivity, and inattention, it is generally acknowledged that ADHD is essentially a cognitive disorder involving a developmental impairment of executive functions (EFs), the brain's controlling system. The major EF domains that are affected by ADHD symptoms include response inhibition, working memory, set-shifting, and planning. Children with ADHD exhibit deficits in behavior disinhibition and cognitive adaptability as well as in judgment, organization, planning, and decision-making. They struggle with social skills as a result, and they also have low self-esteem, a low threshold for frustration, and poor academic success.

The best course of treatment for ADHD in South Africa is specific to each patient and frequently entails a combination of medication, counseling, and/or lifestyle modifications. Both the fundamental symptoms, such as impulsivity or distractibility, as well as the ensuing behavioral and social difficulties should be treated effectively. Stimulants like Ritalin and Adderall are among the most widely prescribed medicines for ADHD. For those who do not react to or cannot handle stimulants, non-stimulants like Strattera or particular classes of antidepressants may be used. Qelbree, a non-stimulant, was authorized in 2021 and 2022 for the treatment of ADHD in infants and adults respectively. Jornay PM and Adhansia XR are two other brand-new stimulant medications for ADHD that were recently authorized by the Food and Drug Administration (FDA) for use in both children and adults. Jornay PM is taken in the evening, in contrast to most stimulants, and starts working by the time the patient wakes up and continues throughout the remainder of the day. Six extended-release capsules of Adhansia XR are offered, some of which contain some of the highest dosage strengths presently on the market.

Market Dynamics

Market Growth Drivers

More individuals are receiving an ADHD diagnosis in South Africa as a result of increased awareness of the condition. More people are seeking treatment for ADHD as knowledge of the condition grows, which is fueling the South Africa ADHD therapeutics market expansion. More people are relocating to cities in South Africa, which is having a rapid urbanization trend. Higher stress levels are linked to urbanization, which may increase the prevalence of ADHD. The market for ADHD therapeutics is anticipated to expand as more people relocate to urban areas.

Market Restraints

South Africa's healthcare system still has funding restrictions, despite improvements in access to treatment. Therefore, some patients might only have limited access to ADHD medications, which might restrain the South Africa ADHD therapeutics market expansion. Many patients in South Africa might not be able to pay the high cost of ADHD medications. Costly prescription drugs may impede market expansion, especially among lower-income groups.

Competitive Landscape

Key Players

• Sonke Pharmaceuticals (ZAF)
• Specpharm (ZAF)
• Afriplex (ZAF)
• Mirren (ZAF)
• Phend Pharma (ZAF)
• Noven Pharmaceuticals
• Otsuka Pharmaceutical
• Purdue Pharma
• RespireRx Pharmaceuticals
• Supernus Pharmaceuticals
• Takeda Pharmaceutical
• Tris Pharma

Healthcare Policies and Regulatory Landscape

The Medicines and Related Substances Control Act, 1965 (Act 101 of 1965) established the South African Health goods Regulatory body (SAHPRA) as the country's national regulatory body (NRA), tasked with ensuring the efficacy, safety, and quality of medical products. The backlog (BL) has been measured by the SAHPRA, and concrete goals have been established for its clearance. To support the new methodologies needed to accomplish this objective, inherited processes and practices have been evaluated, and pilot projects have been launched. These consist of improved document management systems, reorganized work streams with the necessary resources, updated performance contract models, project management tools, and the use of facilitated regulation pathways. (FRPs).